BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29454317)

  • 61. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
    Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
    Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.
    Luo Y; Han R; Evanoff DP; Chen X
    Clin Exp Immunol; 2010 Jun; 160(3):359-68. PubMed ID: 20148913
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial.
    Tan WS; Panchal A; Buckley L; Devall AJ; Loubière LS; Pope AM; Feneley MR; Cresswell J; Issa R; Mostafid H; Madaan S; Bhatt R; McGrath J; Sangar V; Griffiths TRL; Page T; Hodgson D; Datta SN; Billingham LJ; Kelly JD
    Eur Urol; 2019 Jan; 75(1):63-71. PubMed ID: 30274699
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
    Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
    Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 68. What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer?
    Zlotta AR; Van Vooren JP; Denis O; Drowart A; Daffé M; Lefèvre P; Schandene L; De Cock M; De Bruyn J; Vandenbussche P; Jurion F; Palfliet K; Simon J; Schulman CC; Content J; Huygen K
    Int J Cancer; 2000 Sep; 87(6):844-52. PubMed ID: 10956396
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Genetic and immunologic determinants of intravesical BCG therapy in non-muscle-invasive urothelial bladder cancer].
    Krajewski W; Kołodziej A; Dembowski J; Zdrojowy R
    Postepy Hig Med Dosw (Online); 2014 Mar; 68():291-300. PubMed ID: 24662797
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer.
    Gan YH; Zhang Y; Khoo HE; Esuvaranathan K
    Eur J Cancer; 1999 Jul; 35(7):1123-9. PubMed ID: 10533458
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
    Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer.
    Sfakianos JP; Salome B; Daza J; Farkas A; Bhardwaj N; Horowitz A
    Urol Oncol; 2021 Feb; 39(2):121-129. PubMed ID: 33262028
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Overexpression of sialyltransferase CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-Sialyltransferase is related to poor patient survival in human colorectal carcinomas.
    Schneider F; Kemmner W; Haensch W; Franke G; Gretschel S; Karsten U; Schlag PM
    Cancer Res; 2001 Jun; 61(11):4605-11. PubMed ID: 11389097
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo.
    Luo Y; Chen X; O'Donnell MA
    Clin Exp Immunol; 2007 Feb; 147(2):370-8. PubMed ID: 17223980
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunotherapy for non-muscle-invasive bladder cancer: from the origins of BCG to novel therapies.
    Unsworth-White SR; Kitchen MO; Bryan RT
    Future Oncol; 2022 Jan; 18(1):105-115. PubMed ID: 34763531
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.
    Kawai K; Miyazaki J; Joraku A; Nishiyama H; Akaza H
    Cancer Sci; 2013 Jan; 104(1):22-7. PubMed ID: 23181987
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
    Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
    BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
    Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
    Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Gene Expression in Human Polymorphonuclear Neutrophils (PMNs) Stimulated by Bacillus Calmette-Guérin (BCG).
    Liu K; Sun E; Wang L; Nian X; Ma C
    Inflammation; 2020 Dec; 43(6):2098-2108. PubMed ID: 32578048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.